Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortali...
Quick Takeaways: Why It Matters? Elanco is tightening its premium position in canine vaccines by launching the first 0.5 mL combo shot that covers both Lyme disease and leptospirosis in a single, low-volume dose, using its PureFil technology to support fewer reactions and more co...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
Quick Takeaways: Why It Matters? The Roslin partnership positions ProImmune’s Ankyron platform as core enabling infrastructure for veterinary immunology, filling longstanding reagent gaps that have slowed work on livestock, avian, and fish pathogens rel...
Quick Takeaways: Why It Matters? The USDA’s positive safety verdict for Ecovaxxin MG significantly de‑risks US registration, validating ECO’s live‑strain platform and setting up a clear path toward a 2027 filing in a large Mycoplasma gallisepticum market.&nb...
